Biotech Company Reveals Major Data From Acute Myeloid Leukemia Study
Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at European Hematology Association Congress.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult with a healthcare professional for medical advice and treatment.
Real-time information is available daily at https://stockregion.net